Today, Getinge announces its support of the American Heart
Association initiative to build a Cardiogenic Shock Registry. This unparalleled
initiative will enable a wide range of cardiogenic shock research, based on
patient data from hospitals across the US, and lead to opportunities to promote
best practices and improve clinical outcomes.
Historically,
data related to cardiogenic shock has been limited, inconsistent, and
challenging to interpret. If not treated quickly, cardiogenic shock can lead to
organ failure and death. Even when treated timely and at specialized centers,
the rate of survival after cardiogenic shock remains dismal. The American Heart
Association initiative to collect evidence in cardiogenic shock patients across
US hospitals and create a Cardiogenic Shock Registry in collaboration with
academic clinicians, researchers, federal agencies and industry experts, is
unparalleled.
“Cardiogenic
shock is a life-threatening condition where the heart suddenly can’t pump
enough blood to meet the body’s demands, and is often caused by a severe heart
attack or advanced heart failure as a complication of a variety of heart
conditions. It is a common cause of mortality and the management of these
patients remains challenging despite advancement in therapeutic options,” says
Dr. Pierluca Lombardi, Corporate Medical Officer at Getinge.
Getinge
has a long history of providing products and solutions within the
cardiovascular space, making the support to the American Heart Association in
establishing its Cardiogenic Shock Registry very natural.
“The
American Heart Association came up with a brilliant way of fostering
collaboration among experts, and we want to support that. The data collected
will provide high-quality evidence and important best practice treatments for health
care stakeholders”, says Dr. Lombardi. “I’m convinced it will be a game changer
for both clinicians and patients, and a step towards more equal and sustainable
care.”
No comments:
Post a Comment